We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

43 hedge funds and large institutions have $55.2M invested in LogicBio Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

2% less funds holding

Funds holding: 44 → 43 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

36% less capital invested

Capital invested by funds: $86M → $55.2M (-$30.8M)

Holders
43
Holders Change
-1
Holders Change %
-2.27%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
11
Reduced
12
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$3.06M
2
SC
Samlyn Capital
New York
+$455K
3
Northern Trust
Northern Trust
Illinois
+$120K
4
BCM
Bridgeway Capital Management
Texas
+$107K
5
IWM
IHT Wealth Management
Illinois
+$90.7K

Top Sellers

Rank Fund Capital Flow
1
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
California
-$5.3M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.58M
3
SCM
Sio Capital Management
New York
-$906K
4
Morgan Stanley
Morgan Stanley
New York
-$309K
5
OAM
Oxford Asset Management
United Kingdom
-$136K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
26
American International Group
New York
$24K -$2.22K -285 -5%
Morgan Stanley
27
Morgan Stanley
New York
$17K -$309K -39,741 -92%
Barclays
28
Barclays
United Kingdom
$14K -$43.3K -5,573 -67%
Deutsche Bank
29
Deutsche Bank
Germany
$14K -$20.7K -2,656 -48%
Bank of America
30
Bank of America
North Carolina
$14K -$5.21K -670 -19%
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$13.8K +$12.6K +1,614 +136%
Citigroup
32
Citigroup
New York
$11K +$3.55K +457 +27%
TRCT
33
Tower Research Capital (TRC)
New York
$11K +$17.5K +2,249 New
SO
34
STRS Ohio
Ohio
$10K – – –
Legal & General Group
35
Legal & General Group
United Kingdom
$8K – – –
US Bancorp
36
US Bancorp
Minnesota
$4K – – –
AIP
37
Ameritas Investment Partners
Nebraska
$3K – – –
RE
38
RBC Europe
United Kingdom
$1.36K +$2.14K +275 New
Royal Bank of Canada
39
Royal Bank of Canada
Ontario, Canada
$1K -$3.05K -392 -70%
MF
40
Manchester Financial
California
$1K – – –
TFA
41
Toth Financial Advisory
Virginia
$1K – – –
MAM
42
Meeder Asset Management
Ohio
$1K +$2.95K +379 New
BOTOTLSJU
43
Board of Trustees of The Leland Stanford Junior University
California
– -$5.3M -736,827 Closed
SCM
44
Sio Capital Management
New York
– -$906K -125,836 Closed
OAM
45
Oxford Asset Management
United Kingdom
– -$136K -18,923 Closed
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
– -$82K -11,400 Closed
Acadian Asset Management
47
Acadian Asset Management
Massachusetts
– -$15K -2,074 Closed
Bank of Montreal
48
Bank of Montreal
Ontario, Canada
– -$8K -1,093 Closed
CWA
49
Capital Wealth Alliance
Arizona
– -$5K -500 Closed
First Manhattan
50
First Manhattan
New York
– +$778 +100 New
1
2

LOGC Hedge Fund Activity: Q1 2020 in Review

43 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q1 2020, worth a combined $55.2M — down 36% from $86M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of LOGC and 6 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 11 added.

The largest buyer was JP Morgan Chase, adding an estimated $3.06M. The largest seller was Board of Trustees of The Leland Stanford Junior University, exiting entirely with an estimated $5.3M sold.

  • 43 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q1 2020, down from 44 in Q4 2019.
  • Funds reported $55.2M of LogicBio Therapeutics, Inc. Common Stock stock for Q1 2020, down 36% quarter-over-quarter.
  • 6 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q1 2020 and 7 closed out, a net change of -1 holder.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q1 2020 was JP Morgan Chase, an estimated $3.06M added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q1 2020 was Board of Trustees of The Leland Stanford Junior University, an estimated $5.3M sold.

Based on aggregated 13F filings for Q1 2020.